KYMR compared with MDGL: revenue, margins and what each company keeps, and the suppliers and customers both name

KYMRKymera Therapeutics, Inc.

Mkt capRevenueRevenue

MDGLMadrigal Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

KYMRKymera Therapeutics, Inc.

MDGLMadrigal Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

KYMR

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±18.2%▲+0.07%×0.01

Q2 FY26±10.4%▲+1.04%×0.10

Q1 FY26±10.3%▼−0.54%×0.05

Feb 26 '26±11.8%▲+4.80%×0.41

MDGL

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±12.7%▼−8.08%×0.64

Q2 FY26±10.5%▼−9.83%×0.93

= impliedKYMR realized, solidMDGL realized, hatchedOne scale, both sides: full bar = 19%× = |realized| ÷ impliedSource: market data

Q1 FY26

±9.2%

▲+7.42%

×0.80

Feb 19 '26±6.2%▼−11.11%×1.79

KYMRKymera Therapeutics, Inc.

131.73▲+2.82%· post 131.73

Mkt cap$11.2BRevenue$65MQ2 FY26Revenue$39MFY25

MDGLMadrigal Pharmaceuticals, Inc.

396.55▼−0.89%· post 403.00

ClosedNov 6 '26

Mkt cap$9.3BRevenue$431MQ3 FY26Revenue$958MFY25

Compare

ClosedNov 6 '26

KYMRKymera Therapeutics, Inc.

MDGLMadrigal Pharmaceuticals, Inc.

131.73▲+2.82%post 131.73

Price

396.55▼−0.89%post 403.00

$11.2B

Mkt cap

$9.3B

Q2 FY26$65M

Revenue

$431MQ3 FY26

FY25$39M

Revenue

$958MFY25

KYMR131.73▲+2.82%vsMDGL396.55▼−0.89%ClosedNov 6 '26